Monica E. Luchi Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Monica Luchi BBI stock SEC Form 4 insiders trading

Monica has made over 1 trades of the Brickell Biotech Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Monica bought 777,778 units of BBI stock worth $350,000 on 4 August 2016.

The largest trade Monica's ever made was buying 777,778 units of Brickell Biotech Inc stock on 4 August 2016 worth over $350,000. On average, Monica trades about 194,445 units every 0 days since 2016. As of 4 August 2016 Monica still owns at least 777,778 units of Brickell Biotech Inc stock.

You can see the complete history of Monica Luchi stock trades at the bottom of the page.

What's Monica Luchi's mailing address?

Monica's mailing address filed with the SEC is 430 E 29th St #940, New York, NY 10016, USA.

Insiders trading at Brickell Biotech Inc

Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi oraz Gary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.

What does Brickell Biotech Inc do?

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.

Brickell Biotech Inc executives and stock owners

Brickell Biotech Inc executives and other stock owners filed with the SEC include:

• Vijay Samant,
  Director
• Attorney Robert Busard Brown,
  CEO & Director
• Deepak Chadha,
  Chief R&D Officer
• Reginald L. Hardy M.B.A., R.Ph.,
  Co-Founder & Chairman
• Dennison Veru,
  Director
• Gary Lyons,
  Director
• Adam Levy,
  Chief Business Officer
• Deepak Chadha,
  Chief Research and Development Officer
• David McAvoy,
  Chief Compliance Officer, General Counsel, Assistant Secretary
• Jose Breton,
  Chief Accounting Officer, Controller
• R. Carruthers,
  Chief Financial Officer
• Andrew Sklawer,
  Co-Founder, Chief Operating Officer, Secretary
• Robert Brown,
  Chief Executive Officer, Director
• Reginald Hardy,
  Chairman of the Board, Co-Founder
• Sue Fattor,
  Head of Human Resource
• Aron Aizenstat M.B.A., P.M.P.,
  VP of Corp. Devel. & Operations
• Gary S. Walker,
  Chief Marketing Officer
• David R. Mcavoy J.D.,
  Gen. Counsel & Chief Compliance Officer
• Jose Breton,
  Controller & Chief Accounting Officer
• Albert Nicholas Marchio II,
  Chief Financial Officer
• Sanjeev Ahuja,
  Chief Medical Officer
• George B Abercrombie,
  CHIEF EXECUTIVE OFFICER
• Monica E. Luchi,
  Chief Medical Officer
• Albert N Ii Marchio,
  Chief Financial Officer